CIDP – Sanofi EFC17236 MOBILIZE

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.

Specific criteria applies.

Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.